165 results
6-K
EX-1
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
as assessment of the gene modifying potential and senescence of CD34+ cells.
About Sickle Cell Disease
SCD is one of the most common genetic diseases
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
combination demonstrated encouraging disease control and overall survival in patients with metastatic pancreatic cancer. In addition, assessment of patient
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over financial reporting (which is included … will pay additional amounts in respect of any tax, assessment, or governmental charge and, if so, whether we will have the option to redeem the debt
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
such as the assessment of a branded pharmaceutical manufacturer fee and an increase in the amount of the rebates that manufacturers pay for coverage … assessment, we estimate the value of the U.S. stem cell mobilization market at approximately $300 million in 2023.
Multiple myeloma is the second most
F-3
65as9lh 6c1v
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
5tyf7om qlf3n0
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
yahuw8vbpj hr
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
hf1mgxemuij9edt2oa2h
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
no5k4
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
xz0nz1bpkp9p375aduqd
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
9g5dlvftc3stt4 70za
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
424B5
7c4uu pba8
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
bzw2ejx6xc6n7zxuyyid
15 Sep 22
Current report (foreign)
8:39am
20-F/A
9nk0p jt66zzof
9 Sep 22
Annual report (foreign) (amended)
4:15pm
6-K
EX-99
g68fa aqt5q
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
f72xps45cw51u
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
oux8k66ehtmerjdnb3c
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am